A Regional Threat That Is Expanding
In the Phoenix, Arizona metro area, an estimated 6-10% of dogs carry positive titers for Coccidioides — a soil-dwelling fungus that can cause months of chronic cough, bone destruction, and even seizures. Valley fever (coccidioidomycosis) is the most common serious fungal disease in dogs in the Desert Southwest, caused by inhaling spores of Coccidioides immitis or Coccidioides posadasii from disturbed soil. Dogs are far more susceptible than humans, and the disease is a leading cause of unexplained illness in dogs living in or traveling through endemic areas.
Endemic Geography
Core endemic zone: Arizona (especially central and southern), southern California (San Joaquin Valley, Coachella Valley, Los Angeles area), New Mexico (southern), Texas (western), Utah (southwestern), Nevada (southern).
Risk is present throughout the year but highest during periods of drought followed by rain and wind — conditions that mobilize spores from dry soil. Construction, excavation, and dust storms dramatically increase exposure.
Expanding range: documented cases are being reported increasingly outside traditional endemic zones as climate shifts. Dogs and their owners traveling to endemic areas from non-endemic regions face significant risk if unfamiliar with the disease.
How Infection Occurs
Dogs inhale arthrospores (the infectious spore form) from contaminated soil. Spores cannot be transmitted from dog to dog or from dog to human — inhalation of environmental spores is the only route.
After inhalation, spores transform into spherules in the lungs, which rupture to release endospores. Most exposed dogs mount an effective immune response and clear the infection without illness — but a proportion develop progressive pulmonary or disseminated disease.
Clinical Presentations
Pulmonary Valley Fever (Most Common)
- Chronic dry cough that does not respond to antibiotics
- Lethargy and exercise intolerance
- Weight loss
- Fever (often low-grade and intermittent)
- Radiographic: hilar lymphadenopathy (enlarged lung-associated lymph nodes), pulmonary nodules or infiltrates
Key clinical clue: any dog in an endemic area with a chronic non-responsive cough should be tested for valley fever before further diagnostics.
Disseminated Valley Fever
In approximately 20% of affected dogs, infection spreads beyond the lungs:
Skeletal dissemination (most common disseminated form):
- Bone lesions causing lameness, swelling over bones — lytic skeletal lesions can mimic osteosarcoma and should be differentiated using the canine cancer early warning workflow
- Most commonly affects: lumbar spine, long bones, digits
- Radiographic: lytic (destructive) bone lesions
Neurological dissemination:
- Seizures, altered behavior, ataxia
- Meningitis or brain/spinal cord lesions
- Requires aggressive long-term treatment; prognosis variable
Other dissemination sites: skin (subcutaneous nodules, draining tracts), lymph nodes, liver, spleen, heart
Diagnosis
Serology (Titer Testing)
The primary diagnostic test. Measures IgG and IgM antibodies to Coccidioides antigens.
- Positive titer: supports diagnosis in a dog with compatible clinical signs in an endemic area
- Titer magnitude: higher titers correlate with more severe disease; titers are used to monitor treatment response
- Negative titer with high clinical suspicion: does not rule out infection; early infection or immune suppression may produce false negatives; repeat testing in 3–4 weeks
Available through: IDEXX (Cocci test), University of Arizona Veterinary Diagnostic Laboratory (considered reference standard), Arizona Veterinary Diagnostics.
Chest Radiographs
Essential for characterizing pulmonary involvement. Findings: perihilar lymphadenopathy, nodular infiltrates, pulmonary consolidation, pleural effusion (less common).
Other Diagnostics
- CBC/chemistry: non-specific changes (elevated globulins, eosinophilia in some cases)
- Cytology: Coccidioides spherules occasionally visualized in fluid, lymph node aspirates, or skin nodule samples — diagnostic if found
- CT scan: better characterization of pulmonary lesions and bone involvement than radiographs
Treatment
Treatment is antifungal therapy — typically long-term.
Azole Antifungals (First-Line)
Fluconazole: preferred for most cases; good CNS penetration (important for neurological disease); well-tolerated; generic availability reduces cost; typically 5 mg/kg twice daily
Itraconazole: alternative; better activity against some resistant isolates; higher cost; requires monitoring for hepatotoxicity; food significantly affects absorption
Voriconazole: second-line; reserved for refractory cases; more expensive; toxicity in some dogs
Ketoconazole: older agent; liver toxicity concerns; largely replaced by fluconazole/itraconazole
Treatment Duration
This is the most important and most frequently misunderstood aspect of valley fever management.
Pulmonary disease: minimum 6–12 months of antifungal therapy; many dogs require longer Disseminated skeletal disease: 12–24 months minimum; some dogs require lifelong therapy Neurological dissemination: typically lifelong therapy with guarded prognosis
How to determine when to stop: titers are measured every 3–6 months during treatment. Stopping criteria typically include: clinical resolution, stable or declining titers, titer below 1:4 (though some clinicians use 1:2 or negative). Stopping too early leads to relapse — the most common cause of treatment failure.
Cost Awareness
Generic fluconazole is affordable ($20–$50/month for many dogs). Treatment duration of 12–24 months is expensive in aggregate but manageable for most owners. Specialty antifungals (voriconazole) are significantly more expensive.
Relapse and Monitoring
Relapse after discontinuing therapy occurs in a meaningful proportion of dogs. Indicators:
- Return of clinical signs
- Rising titers after previous decline
Dogs with prior valley fever should be monitored with titer checks every 6–12 months indefinitely, even after treatment completion. Valley fever is one of several serious fungal infections affecting dogs regionally, alongside blastomycosis and histoplasmosis.
Prevention
No vaccine is currently available for dogs. Prevention strategies:
- Limit digging behavior (exposure increases with soil disturbance)
- Avoid areas with visible dust or recent excavation
- Keep dogs out of rodent burrow areas (high spore concentrations)
- During high-risk dust events (haboobs, windstorms), keep dogs indoors
No environmental control measure completely eliminates risk in endemic areas. Awareness and early testing for compatible symptoms are more practical than avoidance.
Medical Disclaimer
This guide is for informational purposes only and does not constitute veterinary advice. Consult a licensed veterinarian familiar with regional fungal disease for diagnosis and treatment specific to your dog.
Frequently Asked Questions
Can valley fever be cured? For localized pulmonary valley fever, treatment with azole antifungals (fluconazole, itraconazole) for 6–12 months results in resolution in most dogs, and treatment can be discontinued after confirmed clinical and serologic remission. For disseminated valley fever (infection spread to bones, joints, skin, CNS), lifelong antifungal treatment is often required to prevent recurrence — cure in the true sense is uncommon. Many dogs with disseminated disease live comfortably on long-term low-dose fluconazole.
Is valley fever contagious between dogs, or from dogs to humans? No. Valley fever is not transmitted from dog to dog or from dogs to humans. It is acquired only through inhalation of Coccidioides spores from contaminated soil. There is no risk to other pets or family members from a dog with valley fever. The environmental exposure risk in endemic areas affects dogs and humans independently.
How long after moving to an endemic area does it take for valley fever to develop? Clinical disease typically becomes apparent 1–3 weeks after exposure, although the range is 1–4 weeks. Many dogs (and humans) who inhale Coccidioides spores never develop clinical disease — the immune system contains the infection asymptomatically. Dogs that do develop illness typically show respiratory signs first; dissemination to other organs occurs in a subset over subsequent weeks to months.
How is valley fever diagnosed? The most common diagnostic test is serology — antibody titers (IgM and IgG) against Coccidioides. Titers rise with active infection and decline with successful treatment, making serial titers useful for monitoring treatment response. False negatives occur early in infection before antibody production peaks. Diagnosis can also be made via cytology or culture (though culture is hazardous and rarely performed outside reference labs) or histopathology of affected tissue.
What is the cost of treating valley fever in dogs? Fluconazole (the generic form of Diflucan) is the most commonly used treatment and is relatively affordable — typically $30–80/month for an average-sized dog. Itraconazole is more expensive ($80–200+/month). Long-term or lifelong treatment represents a significant ongoing cost. Many dogs in endemic areas are treated for 1–3+ years; disseminated cases may require permanent treatment.